Expression of somatostatin receptors SSTR1 and SSTR4 on human endothelial cells

摘要

Described is the use of a SSTR1 or SSTR4 (somatostatin receptor subtypes 1 and 4) selective agonist to treat human endothelial cells and to formulate a medicament for human use, where the medicament may be for use to treat an endothelial-cell-mediated proliferative disease. The use of SSTR1 or SSTR4 selective agonists for treating endothelial-cell-mediated proliferative diseases may include, for example, treatment of intimal hyperplasia or an angiogenic disease. In various embodiments, the angiogenic disease may be macular degeneration, or a solid tumour. The SSTR1 or SSTR4 selective agonists may include the SSTR1 '499 agonist (des-AA1,2,5[DTrp8,IAamp9]SS). In methods of treatment, therapeutically effective amounts of the SSTR1 or SSTR4 selective agonists may be administered to a patient.